Is the chronic pain community ON THEIR OWN TO CHANGE THEIR DESTINY ?

Another Pain Organization to Shut Down

www.nationalpainreport.com/another-pain-organization-to-shut-down-8839923.html

Another pain organization apparently is going out of business.

The American Pain Society is filing for bankruptcy and ceasing to exist in its current form.

“It’s a sad day for U.S. pain research, education, advocacy and patient care,” said Stanford’s Beth Darnall, Ph.D., in a tweet this week.

APS is the second pain organization this year to announce it’s shutting down.

The Academy of Integrative Pain announced it was closing down in February. The reasons appear to be similar.

All membership organizations are struggling with the fact that the new generation of doctors are simply joining as previous generations.

“People entering practice after training just aren’t seeing the value in joining organizations. They still want the educational materials and the networking, but much more of that can be done online these days,” said Bob Twillman, Ph.D., who ran AIPM.”

As a result, he said, there’s no need to attend big meetings at resorts or in expensive hotels which tend to attract sponsorship from companies that do business in the specialty.

U.S. Pain Foundation, the largest patient advocacy group in the country, also expressed its sadness that APS is shutting down—terming it “heartbreaking.”

“There are 50 million Americans living with #pain. Hard to believe there are so few orgs left for pain providers. When providers don’t have support and resources, it hurts patients,” US Pain tweeted this week.

One critic of the opioid companies was less charitable.

Andrew Kolodny, M.D. of Physicians for Responsible Opioid Prescribing (PROP) tweeted:

“Good riddance! Despite having many members who understood opioids were lousy drugs for chronic pain, APS took millions from opioids makers, downplayed opioid risks, exaggerated opioid benefits, and lobbied against limits on opioid manufacturer,” he said.

Twillman indicated he believes the reasons for the demise of both AIPM and APS—notably the lack of support from industry and declining membership—may existentially threaten other organizations in the future.

Calls to APS offices in Chicago were not returned.

As thirty odd state AG’s suing more and more parts of those entities and businesses involved in the chronic pain disease management.  More and more are pulling back on their support of various non profits that are advocates for chronic pain treatment and in turn those organizations are losing funding and having to fold their tent.

It all started with Siobhan Reynolds and her Pain Relief Network that was “put out of business” by being targeted by law enforcement and several bureaucratic agencies .. .which in essence forced the non-profit into bankruptcy  https://www.legacy.com/obituaries/santafenewmexican/obituary.aspx?pid=155321117

Now we have two more non profit advocacy groups that are “folding their tents” because of direct/indirect actions of the various bureaucratic agencies.

Does this mean that those in the chronic pain community are ON THEIR OWN to defend their right to appropriate medications and therapies ?  Given what has happened, it is probably best that any non-profit that will be established should seek donations on a monthly basis $5 – $10 for a few million chronic painers would allow the non profit to be active and successful and not sitting on all that many dollars in reserve so that it is less attractive as a target for the bureaucrats.   They come after the non profit… the non profit sends out a notice to all those contributing to STOP… and if somehow they confiscate the $$ in reserve…  the non profit declares bankruptcy and create a new non profit because there is a legion of chronic painers willing to continue to contribute their $5-$10/month to the new non profit.  As far as the bureaucrats are concerned the agenda of the chronic painers will be like trying to catch a “greased pig”.  When the bureaucrats are using the laws against you…  you use the legal system to blunt their attempts to stop you.

A post from SIX YEARS AGO.. has anything changed for the better ?

Lilly selling half-price version of popular Humalog insulin

https://www.apnews.com/f311f61e42684838bb5fd52a4b486215

A half-price version of Eli Lilly’s popular Humalog insulin is now available, following the company’s promise in March to offer diabetics a more affordable option amid fierce criticism of soaring insulin prices.

Lilly, one of the three top insulin makers, said Wednesday that it has begun selling its own generic version of Humalog U-100 under the chemical name insulin lispro.

The Indianapolis drugmaker said insulin lispro will cost $137.35 per vial, or $265.20 for a package of five KwikPens, an easier-to-inject option.

Those figures are half the list price Lilly charges for Humalog. The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.

Lilly said the biggest savings will go to patients who are uninsured, have high-deductible health insurance or have Medicare Part D plans.

Insurers generally pay drugmakers far less than the list price, but many patients must pay a percentage of the list price or the full amount until they meet their health plan’s annual deductible.

Because insulin lispro is identical to Humalog, pharmacists will be able to substitute the half-price generic. However, Lilly noted that some patients will still pay less for Humalog than insulin lispro, depending on their insurance plan.

Patients with diabetes don’t produce enough insulin to control their blood sugar, or their body uses insulin in efficiently, forcing them to inject the hormone, usually several times a day.

The average insulin price nearly tripled from 2002 through 2013, and prices have risen 10% or more a year since then, forcing many diabetics to ration their insulin. Some have ended up in hospitals and a few have died as a result, which has led to congressional hearings on the issue.

DEA: how many ways can I fine you… let me COUNT THE WAYS

DEA and U.S. Attorney in the Western District of Louisiana announce settlement with drug distributor

https://www.therolladailynews.com/news/20190524/dea-and-us-attorney-in-western-district-of-louisiana-announce-settlement-with-drug-distributor

Morris & Dickson Company LLC has agreed to pay the United States $22 million in civil penalties to resolve claims that it violated the Controlled Substances Act by failing to report suspicious orders of hydrocodone and oxycodone, announced Drug Enforcement Administration Special Agent in Charge Brad L. Byerley and United States Attorney David C. Joseph.

“The failure to report suspicious orders as required by federal regulations contributes to the opioid epidemic, which has caused devastating harm to individuals and our communities,” said Special Agent in Charge Byerley. “The settlement with Morris & Dickson demonstrates the resolve by DEA to use all available tools to address this crisis at every level and reduce the availability of highly addictive, dangerous drugs.”

“The fight against opioid abuse is among our nation’s most pressing law enforcement and public health initiatives,” said U.S. Attorney Joseph. “Opioids are now the leading cause of accidental death in the United States – killing approximately 130 Americans every day. About 40 percent of these deaths involve prescription drug abuse. This settlement demonstrates the Justice Department’s continued commitment to use all of the tools at its disposal to stem the opioid epidemic. Louisiana citizens should know that my office and our local DEA agents will continue to investigate and aggressively prosecute any manufacturer, distributor, pharmacy or doctor who, whether negligently or intentionally, fail in their duty to appropriately control the distribution and use of these deadly drugs.”

In addition to paying $22 million in settlement funds, Morris & Dickson also agreed during the course of the negotiations to make significant upgrades to its compliance program by investing millions of dollars to hire additional staff and implement new protocols and standards to ensure compliance with federal regulations requiring them to report suspicious orders of controlled substances.

This settlement arises from a DEA Office of Diversion Control investigation into Morris & Dickson’s failure to report suspicious orders of hydrocodone and oxycodone. Since January 2014, DEA Diversion agents have identified more than 12,000 allegedly suspicious retail pharmacy orders that should have been reported. Under the Controlled Substances Act and its implementing regulations, distributors are required to report suspicious orders to the DEA. Reporting suspicious orders and maintaining effective controls against diversion of controlled substances are critical components of the government’s effort to stop the illegal distribution and sale of opioids.

Morris & Dickson is the largest privately owned wholesale pharmaceutical distributor in the United States and the fourth largest wholesale distributor in the country, reporting total revenues of over $4 billion in its fiscal year ending Jan. 31, 2018. Since January 2014, Morris & Dickson distributed controlled substances to approximately 800 retail pharmacies across 17 states, distributing over 600,000,000 dosage units. Morris & Dickson services hospitals, alternative and other health care providers, and retail pharmacies out of its Shreveport, La., facility.

The Centers for Disease Control and Prevention estimates that more than 630,000 Americans died from drug overdoses from 1999 to 2016. In 2016 alone, approximately 42,000 people died of opioid-related causes. The number of opioid-overdose deaths has reached epidemic proportions: In 2016 there were five times as many such deaths as there were in 1999.

To report suspected opioid-related crimes, the public is encouraged to contact the DEA at www.deadiversion.usdoj.gov/tips_online.htm.  

 

Stool Pigeon Hyperlink ——–> www.deadiversion.usdoj.gov/tips_online.htm.  

OHIO: Overdose deaths rising this year over 2018

https://www.wdtn.com/news/local-news/overdose-deaths-trending-higher-this-year-than-2018/2021146019

DAYTON, Ohio (WDTN) – Drug overdose deaths for 2019 are out-pacing 2018, according to Montgomery County Coroner Kent Harshbarger. 

As of May 16, the coroner’s office counted 102 deaths for 2019 vs. 105 through the end of May in 2018. Harshbarger said he expected the 2019 numbers through May to be higher than 2018 once the month is finished and official reports are finished for March, April and May. 

Harshbarger said most overdose cases he’s seen are a mix of drugs in the systems of the deceased, with fentanyl being the cause of death. The drug is sometimes combined with methamphetamine or cocaine, or on some occasions, all three.

Overdose numbers are still below the numbers in 2017 with 566 for the year and 81 deaths in May 2017 alone.

The overdose surge in May 2017 was due to carefentanil, a fentanyl analog exponentially more powerful than heroin.

“A lot of the analogs are gone,” Harshbarger said. “Most are illicit fentanyl, not the prescription. We hardly ever see heroin, and if we do it’s mixed with fentanyl, cocaine or meth.” 

Harshbarger said any overdose death is alarming, but said community’s work in addressing the opioid crisis over the last several years has given people more options for help. 

“It’s certainly not as bad as 2017,” Harshbarger said. “There are more programs and more options for people in the community in need of help.” 

Benzo co-prescribed for MAT for substance abusers BUT NOT FOR CHRONIC PAINERS ?

FDA Okays Benzodiazepines and Medication-Assisted Opioid Addiction Treatment

https://www.drugtopics.com/clinical-news/fda-okays-benzodiazepines-and-medication-assisted-opioid-addiction-treatment

The FDA has issued a Drug Safety Communication on the use of benzodiazepines and opioid addiction medications. Benzodiazepines and other drugs that can depress the central nervous system do not have to be withheld from patients taking drugs such as buprenorphine or methadone for treatment of opioid addiction. However, careful medication management is needed to reduce the risks of serious side effects.

“The combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks,” the FDA stated in its safety communication. “Careful medication management by health-care professionals can reduce these risks.”

The new information will be added to labeling for buprenorphine and methadone, along with detailed recommendations for minimizing the use of medication-assisted treatment (MAT) drugs and benzodiazepines together. Side effects of combining opioids and benzodiazepines include dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness.

Many people who are addicted to or dependent on opioids also take benzodiazepines or other CNS depressants either licitly to treat anxiety and other conditions or illicitly. The FDA recommends that a patient’s treatment plan should include several actions or precautions if buprenorphine or methadone are used in combination with CNS depressants. These include:

  • Educate MAT patients about the serious risks of combined use that can occur with CNS depressants.
  • Develop strategies to manage the use of prescribed or illicit benzodiazepines or other CNS depressants when starting MAT.
  • Taper the benzodiazepine or CNS depressant to discontinuation if possible.
  • Verify the diagnosis if a patient is receiving prescribed benzodiazepines or other CNS depressants for anxiety or insomnia, and considering other treatment options for these conditions.
  • Recognize that patients may require MAT medications indefinitely and their use should continue for as long as patients are benefiting and their use contributes to the intended treatment goals.
  • Coordinate care to ensure other prescribers are aware of the patient’s buprenorphine or methadone treatment.
  • Monitor for illicit drug use, including urine or blood screening.

This safety announcement is based on additional review of the use of these drugs together that caused the agency to update a previous communication. In late August 2016, the FDA had issued a strong warning against combining opioid medicines, including cough medicines, with benzodiazepines. 

NO DEAD BODIES: DEA: doctor is believed to still be over-prescribing prescription medications..office raided

Florence doctor surrendered license, prescriptions revokedFlorence doctor surrendered license, prescriptions revoked

https://www.wlbt.com/2019/05/23/florence-doctor-surrendered-license-prescriptions-revoked/

JACKSON, Miss. (WLBT) – A doctor whose Florence office was raided Monday by the Drug Enforcement Agency, the Mississippi Bureau of Narcotics, and others surrendered his license under pressure on Monday around the time his office was raided.

That’s according to the Mississippi Board of Medical Licensure. Dr. Ken Cleveland of the Board said Dr. Van Coleman has also surrendered his DEA number, which means all of his current prescriptions are no longer valid.

The investigation into Coleman started in 2018, but it was not the first time he had been under scrutiny. In 2013, he was required to take a prescribing course in lieu of being punished for failing to acknowledge that some of his patients were doctor shopping. The investigation continues, and we’re told others have also been arrested.

DEA Acting Special Agent Christopher Daniel said Coleman is believed to still be over-prescribing prescription medications.

Looking for evidence, search warrants were served on Coleman’s office in the Florence Family Medical Clinic and at his home. Authorities said he is not charged yet, but charges are forthcoming.

The Mississippi Boards of Nursing, Pharmacy, and Medical Licensure were involved with the investigation, as well as the Bureau of Alcohol Tobacco Firearms and Explosives, the Rankin County Sheriff’s Department, and the Department of Health and Human Services.

“VA has demonstrated success in reducing opioid use, while addressing the challenge of living well with chronic pain.”

VA Secretary praises department’s model path to ending opioid addiction

Statement follows President Trump’s remarks at summit addressing drug crisis

www.blogs.va.gov/VAntage/59377/va-secretary-praises-departments-model-path-ending-opioid-addiction/#comments

Calling the U.S. Department of Veterans Affairs a recognized leader in pain management and opioid safety, VA Secretary Robert Wilkie today underscored the department’s innovative approaches to chronic pain management.

Wilkie’s response followed President Trump’s speech April 24 at the annual Rx Drug Abuse & Heroin Summit in Atlanta, where stakeholders gathered to discuss prevention, treatment and actions to curtail the opioid crisis.

“More than 100 million Americans suffer from some form of chronic pain, and the overuse and misuse of opioids for pain management in our country is taking too many lives,” Wilkie said. “Veterans who have served our nation are particularly challenged by chronic pain. VA has demonstrated success in reducing opioid use, while addressing the challenge of living well with chronic pain.”

Over the past six years, VA’s Opioid Safety Initiative (OSI) has reduced opioid dispensing more than 50%. Most of this reduction is attributable to not starting new, long-term opioid therapy in Veterans with chronic pain.

Specifically, VA is not starting Veterans with chronic, noncancer pain on long-term opioid therapy, but is instead offering them complementary pain management strategies. These treatments include use of complementary therapies, such as acupuncture, yoga, chiropractic medicine, tai chi and bio-feedback, among other modalities, and have proven to be more effective for Veterans long term. Veterans are 40 percent more likely to have severe, chronic pain than non-Veterans.

VA has employed four broad strategies to address the opioid epidemic: education, pain management, risk mitigation and addiction treatment. VA addressed the problem of clinically inappropriate high-dose prescribing of opioids, while developing an effective system of interdisciplinary, patient-aligned pain management to provide safe and effective pain control. In the process, VA trained hundreds of clinicians on this approach to pain management.

VA’s approach is Veteran-centric and whole health. By understanding the Veteran’s goals and lifestyle and incorporating a variety of therapeutic treatments, Veterans are now achieving success in managing chronic pain.

VA continues to offer full transparency of its efforts to reduce opioid prescribing. To learn about the VA Opioid Safety Initiative or for more information on VA pain management, go to www.va.gov/painmanagement.

“I believe I am a danger to the public working for CVS.” – Anonymous CVS Pharmacist

“I believe I am a danger to the public working for CVS.”

http://pharmacistactivist.com/2019/May_2019.shtml

Background

I have been a pharmacist long enough to remember the time when CVS was first started. Its leadership demonstrated a strong commitment to the professional role of pharmacists and their communication with patients. Television advertisements featured pharmacists counseling patients. I encouraged my students who were interested in a position in a chain pharmacy to seek an opportunity with CVS.

Very unfortunately, for both pharmacists and consumers, things have radically changed. Yes, smiling pharmacists are still featured in CVS advertisements. However, the reality of the employment experience of many CVS pharmacists has markedly deteriorated, even to the point of being dangerous.

The anonymous pharmacist (AP) who made the comment that is the title of this editorial is not one of my former students, but is known to me as an individual who is very caring and has the courage to communicate concerns. When AP learned that the Board of Pharmacy was holding a meeting at which pharmacy policies and working conditions would be discussed, AP submitted a letter. AP’s letter had to be submitted anonymously because, as AP stated in a separate message to me, “I know I would be terminated immediately for speaking against my employer.” The letter AP sent to the Board of Pharmacy includes the following statements:

“Since the Aetna buyout we have noted increased pressure to provide pharmacy services with reduced staffing. This includes both pharmacists and technicians.”

“The company routinely ignores pharmacist to technician ratio.”

“Technicians and pharmacists are required to sign up people for refill or 90 days prescriptions or scriptsync without their permission. This causes unwanted prescriptions to be sold and then they are brought back and yes we give them their money back and some of the drugs make it back on the shelf, especially inhalers and high dollar items. CVS management will lie about this. Sit a few of them down and administer a lie detector test and watch them squirm.”

“Requiring pharmacists and technicians to work off the clock is a common practice…Most pharmacists come in early, stay late, and, if we complain, we are told the job needs to be done, just work faster, watch your dashboard, and stay out of the red.”

“We keep the fast food places in business because the pharmacists are always buying lunches for the techs and they cannot take lunch because we are behind. They never get their break that is also required by law.

“I invite the regulator agents to visit and check a few profiles and see how many customers have no allergy information entered. CVS is more interested in the metrics, converting to the drug that costs CVS the least. We have been instructed by district leaders to scan our credentials when it appears in the QV screen to indicate we have talked to a patient.”

“Please take action. I am speaking for many silent pharmacists.”

This pharmacist must remain anonymous because, as difficult as AP’s working conditions are, AP must keep the position with CVS as there are not other employment opportunities for pharmacists available in that geographical area, a situation that now exists in many parts of the country. I am not in a position to judge, and do not fault any pharmacist for her or his decision regarding employment. However, when circumstances arise which place patients at risk, pharmacists must have the courage demonstrated by this pharmacist in making concerns known, even when it must be done anonymously. I was motivated by AP’s action and I have also written a letter to that Board of Pharmacy.

* * * * * * *

April 29, 2019

To the Members of the _________ State Board of Pharmacy:

It is my understanding that you will be discussing policies and working conditions in pharmacies, and I wish to share my concerns that are based on information communicated to me by pharmacists who are employed in chain pharmacies. I am a pharmacist, and recently retired after 52 years as a member of the faculty at the Philadelphia College of Pharmacy at the University of the Sciences. I continue to write a monthly newsletter, The Pharmacist Activist (www.pharmacistactivist.com) in which I provide editorials and reviews of new drugs. Many of my editorials address concerns regarding patient safety in the use of medications, and the working conditions of pharmacists and pharmacy technicians.

I have received hundreds of responses to my editorials from pharmacists with whom I speak at meetings of pharmacy organizations, and via email and telephone communications. In addition, I have served as an expert witness in a number of lawsuits in which patients have been harmed because of dispensing errors or other medication-related problems. By far, the largest number of concerns of which I have been made aware are communicated to me by pharmacists working at CVS stores. The most common concerns that are provided include the following:

  1. Concerns about patient safety and errors that are attributable, at least in part, to management-imposed policies, quotas, and working conditions.
  2. Understaffing of pharmacists and pharmacy technicians that results in a stressful and error-prone workplace environment.
  3. Policies and metrics that emphasize numbers (e.g., prescriptions, immunizations) and how quickly responsibilities can be completed (e.g., time to dispense a prescription).
  4. Insufficient time to speak with patients about medications dispensed.
  5. Policies and procedures with respect to how dispensing errors are to be handled.
  6. Inadequate compensation for pharmacy technicians that results in frequent turnover and extra time required to train new technicians. As one example, a pharmacy manager informed me that when a Wendys restaurant opened nearby, five of the technicians left to work at Wendys because of its higher hourly wage.
  7. No or insufficient authority to fire technicians who make frequent mistakes or who otherwise perform inadequately.
  8. Having supervisors who are not pharmacists, that is occurring with increasing frequency.
  9. Work schedules (e.g., 12- and 14-hour days with no or limited breaks; difficulty in scheduling days off/vacation time) that contribute to stress and errors. I often hear comments such as, “When I finish a long shift at the pharmacy, I am so tired that the specific activities of the day are a blur, and I only pray that there were no serious errors.”
  10. Having to designate customers to receive automatic refills when they do not request it or even decline it.
  11. Having to work “off the clock” without pay to complete activities the company expects to be done within defined time periods.
  12. Fear of termination or retaliation if concerns are voiced. An increasingly frequent response from a supervisor is the following: “If you don’t like the way things are done here, I have five applications from pharmacists who would love to have your job, and maybe you should consider another opportunity.” Forms of retaliation have included assignment to another pharmacy with the chain that is a farther distance from the pharmacist’s home, or assignment to be a “floater” among several pharmacies on an unpredictable schedule. One chain pharmacist has told me that if a concern was voiced about working conditions at a meeting of the Board of Pharmacy, the pharmacist would be terminated before leaving the room.

I have written in greater depth regarding some of these concerns in many of my editorials. I would be glad to provide copies if it would be helpful.

There is information that chain pharmacies would have available that would be of value in your consideration of these matters. This information includes:

  • the criteria for determination of the number of pharmacist hours and pharmacy technician hours for a pharmacy;
  • the metrics that are used in the procedures for processing and dispensing prescriptions;
  • the time within which a prescription is expected to be dispensed following receipt (including warnings/signals about the amount of time elapsed);
  • procedures in which pharmacists at remote sites are involved in the review and processing of prescriptions;
  • bonuses that are based on the number of prescriptions completed, and;
  • records of dispensing and other errors, as well as resultant reports (e.g., to the Board of Pharmacy) and actions taken.

If I can be of assistance, please feel free to contact me.

Sincerely,
Daniel A. Hussar
Author/editor of The Pharmacist Activist

* * * * * * *

More action needed

I have intentionally not identified the state in which this pharmacist practices or the specific board of pharmacy because I believe that the situations and concerns are of the greatest importance and exist in every state. If the concerns identified are ones you have experienced or otherwise share, I encourage you to communicate them to your State Board of Pharmacy or other appropriate authorities. If it will help, provide a copy of this issue of The Pharmacist Activist in support of your concerns. If you wish to do so, please use all or part of the above information verbatim as your own message – it is not necessary to identify me or the anonymous pharmacist as the source, and this statement provides permission to do that.

If you have had personal experiences or are otherwise aware of situations that are pertinent with respect to the matters addressed, I am interested in learning about them, as well as actions you are taking.

Daniel A. Hussar
danandsue3@verizon.net

CVS Detroit: OD in AISLE TWO

Heroin addict almost dies of overdose in CVS on 8th Mile and Grat